<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03961204</url>
  </required_header>
  <id_info>
    <org_study_id>MS700568_0026</org_study_id>
    <secondary_id>2019-000069-19</secondary_id>
    <nct_id>NCT03961204</nct_id>
  </id_info>
  <brief_title>Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for Multiple Sclerosis (MS)</brief_title>
  <acronym>CLASSIC-MS</acronym>
  <official_title>Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the long-term outcomes, durability of effect, and
      real world treatment patterns in participants previously participating in the Phase 3 oral
      cladribine in early multiple sclerosis (ORACLE MS) and Oral Cladribine in participants with
      relapsing remitting multiple sclerosis, extension study (CLARITY/CLARITY-EXT) clinical trials
      with the study number of 28821 (NCT00725985), 25643 (NCT00213135) and 27820 (NCT00641537)
      respectively.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Using Wheelchair Assessed by Expanded Disability Status Scale (EDSS) Score 7.0 or Higher</measure>
    <time_frame>Within 2 weeks of signing the informed consent form</time_frame>
    <description>EDDS is a scale from 0-10 that evaluates a person with MS disability/neurologic function level where 0=normal and 10=death due to MS. Score of 7.0 is defined as unable to walk beyond approximately 5 meters even with aid, essentially restricted to wheelchair; wheels self in standard wheelchair and transfers alone; up and about in wheelchair some 12 hours a day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with 3-Month Sustained Expanded Disability Status Scale (EDSS) Score 6.0 or Higher</measure>
    <time_frame>Within 2 weeks of signing the informed consent form</time_frame>
    <description>EDDS is a scale from 0-10 that evaluates a person with MS disability/neurologic function level where 0= normal and 10= death due to MS. Score of 6.0 is defined as &quot;intermittent or unilateral constant assistance cane, crutch, brace required to walk about 100 meters with or without resting&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each Category of Clinical Characteristics</measure>
    <time_frame>Within 2 weeks of signing the informed consent form</time_frame>
    <description>Clinical characteristics included gender, age/year of birth, race, ethnicity, education, employment status, disease modifying treatment and disease classification (relapsing remitting multiple sclerosis [RRMS] or Secondary Progressive Multiple Sclerosis [SPMS]). Number of participants in each category of clinical characteristics will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Duration</measure>
    <time_frame>Within 2 weeks of signing the informed consent form</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Duration</measure>
    <time_frame>Within 2 weeks of signing the informed consent form</time_frame>
    <description>A relapse will be defined as participant-reported symptoms and objectively observed signs typical of an acute inflammatory demyelinating event in the central nervous system (CNS), developing acutely or sub-acutely, with duration of at least 24 hours, in the absence of fever or infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Volume of Time Constant 2 (T2) Lesions</measure>
    <time_frame>Within 6 weeks of signing the informed consent form</time_frame>
    <description>Total Volume of T2 Lesions will be measured by Using Magnetic Resonance Imaging (MRI) Scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Time Constant 2 (T2) Lesions</measure>
    <time_frame>Within 6 weeks of signing the informed consent form</time_frame>
    <description>T2 Lesions will be measured by Using MRI Scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Time Constant 1 (T1) Hypointense Lesions</measure>
    <time_frame>Within 6 weeks of signing the informed consent form</time_frame>
    <description>T1 Hypointense Lesions will be measured by Using MRI Scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Volume</measure>
    <time_frame>Within 6 weeks of signing the informed consent form</time_frame>
    <description>Brain volume will be measured by Using MRI Scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Volume</measure>
    <time_frame>Within 6 weeks of signing the informed consent form</time_frame>
    <description>Ventricular Volume will be measured by Using MRI Scans.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">971</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cladribine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Participants will not receive any investigational medicinal product (IMP) in the study. Participants will be eligible who had participated in parent studies 25643 (NCT00213135), 27820 (NCT00641537) and 28821 (NCT00725985) and had received Cladribine tablets or placebo.</description>
    <arm_group_label>Cladribine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with relapsing remitting multiple sclerosis (RRMS) randomised in
             CLARITY/CLARITY-EXT clinical trial(s) who have received greater than or equal to (&gt;=)
             1 course of in investigational medicinal product (IMP) Cladribine Tablets or placebo

          -  Participants with their first clinical demyelinating event randomised in ORACLE MS
             clinical trial who have received &gt;= 1 course of IMP Cladribine Tablets or placebo

          -  Participants who has sign informed consent which includes compliance with the
             requirements and restrictions listed in the informed consent form and this protocol

        Exclusion Criteria:

          -  Participants who has any uncontrolled disease state other than MS, that in the
             Investigator's opinion, constitutes an inappropriate risk or a contraindication for
             participation in the study or that could interfere with the study objectives, conduct,
             or evaluation

          -  Female study participants who are pregnant

          -  Participants who are taking Cladribine Tablets as part of another study at the time of
             the start of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
    <email>eMediUSA@emdserono.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MS Center of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>j.english@mscatl.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey B English</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Baltimore - Maryland Center for MS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>hrus@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Horea G Rus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Empire Neurology, PC - Empire Neurology PC</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <zip>12110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kedwards@tristateneuro.com</email>
    </contact>
    <investigator>
      <last_name>Keith R Edwards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Neuro Health Center - Neurology</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>susan.scarberry@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Susan L Scarberry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OMRF</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>gabriel-pardo@omrf.org</email>
    </contact>
    <investigator>
      <last_name>Gabriel Pardo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rowan University School of Osteopathic Medicine - Department of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>dbarone23@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Donald A Barone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Sydney</name>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>michael@sydneyneurology.com.au</email>
    </contact>
    <investigator>
      <last_name>Michael H Barnett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barmherzige Brueder Konventspital Linz - Abteilung fuer Neurologie</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>christian.eggers@posteo.de</email>
    </contact>
    <investigator>
      <last_name>Christian Eggers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Liege</name>
      <address>
        <city>Seraing</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>dominique.dive@chuliege.be</email>
    </contact>
    <investigator>
      <last_name>Dominique Dive</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy - MHAT - Pleven</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>medika@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Plamen Tzvetanov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MHAT - Shumen, AD</name>
      <address>
        <city>Shumen</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>dr_i5@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ivaylo Petrov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital &quot;Saint Naum&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>balnp@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ivan G Milanov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Stara Zagora</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>manolovats@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Theodora Manolova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Neuro-Outaouais</name>
      <address>
        <city>Gatineau</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>francois.jacques@neuro-outaouais.ca</email>
    </contact>
    <investigator>
      <last_name>Francois H Jacques</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Recherche Sepmus, Inc.</name>
      <address>
        <city>Greenfield Park</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>fgrandm@videotron.ca</email>
    </contact>
    <investigator>
      <last_name>Francois Grand'Maison</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mfreedman@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Mark S Freedman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Privatni ordinace - neurologie - Nestatni zdravotnicke zarizeni</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>radomir.talab@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Radomir Talab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc - Neurologicka klinika</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jan.mares@fnol.cz</email>
    </contact>
    <investigator>
      <last_name>Jan Mares</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava - Dept of Neurology</name>
      <address>
        <city>Ostrava-Poruba</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ivana.woznicova@fno.cz</email>
    </contact>
    <investigator>
      <last_name>Ivana Woznicova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze - Dept of Neurologicka klinika 1.LF UK a VFN v Praze</name>
      <address>
        <city>Praha 2</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ivana.kovarova@vfn.cz</email>
    </contact>
    <investigator>
      <last_name>Ivana Kovarova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole - Interní klinika 2. LF UK a FN Motol</name>
      <address>
        <city>Praha 5</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>libertinova@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jana P Libertinova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krajska zdravotni, a.s. - Nemocnice Teplice, o.z. - Neurologicke oddeleni</name>
      <address>
        <city>Teplice</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>marta.vachova@kzcr.eu</email>
    </contact>
    <investigator>
      <last_name>Marta Vachova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Astra Team Clinic</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>katrin.gross-paju@keskhaigla.ee</email>
    </contact>
    <investigator>
      <last_name>Katrin Gross-Paju</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>irja.kalbe@kliinikum.ee</email>
    </contact>
    <investigator>
      <last_name>Irja Kalbe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuro NEO Oy - NEO Research</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>juha-pekka.eralinna@mehilainen.fi</email>
    </contact>
    <investigator>
      <last_name>Juha-Pekka Eralinna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro - CHU Lille - service de neurologie D</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>patrick.vermersch@univ-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick Vermersch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Carémeau - Service de Neurologie</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>giovanni.castelnovo@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Giovanni Castelnovo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hopital Pontchaillou - Neurologie - Clinique Neurologique</name>
      <address>
        <city>Rennes cedex 09</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>emmanuelle.lepage@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle Le Page</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ltd. Pineo Medical Ecosystem</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>alexander.tsiskaridze@tsu.ge</email>
    </contact>
    <investigator>
      <last_name>Alexander Tsiskaridze</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S. Khechinashvili University Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>marjaneli@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Marina Janelidze</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Und Poliklinik Fur Neurologie</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>klemens.angstwurm@medbo.de</email>
    </contact>
    <investigator>
      <last_name>Klemens Angstwurm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico V. Emanuele - Presidio Gaspare Rodolico - Clinica Neurologica I</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>patti@unict.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Patti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Clinicizzato SS. Annunziata - Centro Regionale Sclerosi Multipla</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>gio.deluca05@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Giovanna De Luca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele - U.O. di Neurologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>filippi.massimo@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Filippi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria &quot;Federico II&quot; - Gastroenterologia Pediatrica</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>vincenzo.bresciamorra2@unina.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Brescia Morra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero_Universitaria S. Luigi Gonzaga - Centro di Riferimento Regionale Sclerosi Multipla</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>antonio.bertolotto@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Bertolotto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Istituto Neurologico Casimiro Mondino - Unità Complessa Malattie Cerebrovascolari/Stroke U</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>roberto.bergamaschi@mondino.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Bergamaschi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza - Neurologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>carlo.pozzilli@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Carlo Pozzilli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>hojinkim@ncc.re.kr</email>
    </contact>
    <investigator>
      <last_name>Ho-Jin Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kimsm@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Seung Min Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kaunas Clinics - Neurology Clinic</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>antanas.vaitkus@kaunoklinikos.lt</email>
    </contact>
    <investigator>
      <last_name>Antanas Vaitkus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital - PARENT</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>harald.hovdal@stolav.no</email>
    </contact>
    <investigator>
      <last_name>Harald Olav Hovdal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital im. Mikołaja Kopernika - Neurology</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>w.fryze@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Waldemar Fryze</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im.Heliodora Swiecickiego Uniwersytetu Medycznego im.K. Marcinkowskiego w Poznaniu - Dept of Neurology</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>wkozubski@ump.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Wojciech Kozubski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Central, E.P.E. - Hospital de Santo António dos Capuchos - Serviço de Neurologia</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>joana_parra@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Joana Parra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SAIH &quot;Kemerovo Regional Clinical Hospital&quot; - PARENT</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>bambyk42@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Elena G Arefeva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BMI &quot;Kursk Regional Clinical Hospital&quot;</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>etretyakova08@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Evgeniya Tretyakova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHI &quot;Central Clinical Hospital #2 of JSC &quot;Russian Railways&quot; n.a. N.A. Semashko</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ovvorobeva@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Olga V Vorobyeva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBIH of Moscow &quot;City Clinical Hospital # 24&quot; - Branch 1</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>boykoan13@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alexey N Boyko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBIH of Moscow region &quot; Moscow Regional Scientific and Research Clinical Institute n.a. M.F. Vladimi</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kotovsv@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Sergey V Kotov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medis</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>irsokol@inbox.ru</email>
    </contact>
    <investigator>
      <last_name>Irina Sokolova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RSHI&quot;State Novosibirsk Regional Clinical Hospital&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>yadan1@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Nadezhda Malkova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SEIHPE &quot;Rostov State Medical University of MoH of RF&quot;</name>
      <address>
        <city>Rostov-on-don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>balyazin.victor@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Victor A Balyazin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LLC &quot; International Clinic MEDEM&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>oamelina@sogaz-clinic.ru</email>
    </contact>
    <investigator>
      <last_name>Olga A Amelina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pavlov First Saint Petersburg State Medical University - PARENT</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ntotolyan@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Natalia A Totolyan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBIH &quot;Leningrad Regional Clinical Hospital&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>olgluk@inbox.ru</email>
    </contact>
    <investigator>
      <last_name>Olga N Lukinykh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBIH &quot;Samara Regional Clinical Hospital n.a. V.D. Seredavin</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ipover555@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Irina E Poverennova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBEI HPE &quot;Saratov State Medical University n.a. V. I. Razumovskiy&quot; of the MoH of the RF</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>nicolaymak@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Nikolay S Makarov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RSBIH &quot;Smolensk Regional Clinical Hospital&quot;</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>maslovasm@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Natalia N Maslova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg SU on b.o. City Multifield Hospital #2 - Intensive Pulmonology and Thoracal Surgery</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>gmpb2nd2@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Semeon V Perfilyev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siberian State Medical University</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>v_alifirova@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Valentina M Alifirova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Multiple Sclerosis Centre b/o CC ECM &quot;Neftyanik&quot; - Neurology</name>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sivertseva@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Stella A Sivertseva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBHI of Yaroslavl Region &quot;Clinical Hospital # 8&quot; - Cardiology</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>nnspirin@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Nikolay N Spirin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>drulovicjelena@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jelena Drulovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center Nis - Clinic of Neurology</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>slobodan.vojinovic@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Slobodan Vojinovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>doctoredu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eduardo Agüera Morales</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Sjukhuset</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jan.lycke@neuro.gu.se</email>
    </contact>
    <investigator>
      <last_name>Jan Lycke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>(CHUV), Centre Hospitalier Universitaire Vaudois - Departement des Neurosciences Cliniques</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>marie.theaudin@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Marie Theaudin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SI Institute of Neurology, Psychiatry and Narcology of NAMSU - Dept of Neuroinfections and Multiple Sclerosis</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>proapril@ukr.net</email>
    </contact>
    <investigator>
      <last_name>Nataliya P Voloshyna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vinnitsa State Medical University - Neurology dept</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mosk6565@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sergii P Moskovko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospital - Division of Clinical Neurology</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>cris.constantinescu@nottingham.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Cris Constantinescu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital - Dept of Neurology</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>basil.sharrack@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Basil Sharrack</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS700568_0026</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Cladribine</keyword>
  <keyword>High Disease Activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

